LIGHTOX

Precision light-activated therapeutics and translational imaging tools

LightOx develops next-generation light-activated small molecules that selectively target and destroy diseased cells upon illumination. This highly controllable mechanism enables localized treatment with minimal off-target effects. The company’s lead programs focus on Head & Neck cancers and dermatological indications, where targeted cell killing can significantly improve safety and clinical outcomes.

In parallel, LightOx offers a suite of advanced fluorescent probes for cellular and subcellular imaging, supporting researchers in visualizing, tracking, and quantifying biological processes with high precision. These tools accelerate discovery and provide unique mechanistic insights across the life sciences.

LightOx is also developing specialized light-delivery equipment to enable controlled activation in laboratory and translational research settings, further expanding the applicability of its platform.

More information: www.lightox.co.uk